487 related articles for article (PubMed ID: 20819100)
1. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Hurmuzlu M; Aarstad HJ; Aarstad AK; Hjermstad MJ; Viste A
Dis Esophagus; 2011 Jan; 24(1):39-47. PubMed ID: 20819100
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in long-term esophageal cancer survivors after potentially curative treatment.
Courrech Staal EF; van Sandick JW; van Tinteren H; Cats A; Aaronson NK
J Thorac Cardiovasc Surg; 2010 Oct; 140(4):777-83. PubMed ID: 20554296
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
[TBL] [Abstract][Full Text] [Related]
7. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
9. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
11. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Hurmuzlu M; Monge OR; Smaaland R; Viste A
Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
[TBL] [Abstract][Full Text] [Related]
12. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
13. Impacts of treatments on the quality of life among esophageal squamous cell carcinoma patients.
Chen CY; Hsieh VC; Chang CH; Chen PR; Liang WM; Pan SC; Shieh SH
Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859389
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma.
Blazeby JM; Sanford E; Falk SJ; Alderson D; Donovan JL
Cancer; 2005 May; 103(9):1791-9. PubMed ID: 15779022
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Sunde B; Klevebro F; Johar A; Johnsen G; Jacobsen AB; Glenjen NI; Friesland S; Lindblad M; Ajengui A; Lundell L; Lagergren P; Nilsson M
Br J Surg; 2019 Oct; 106(11):1452-1463. PubMed ID: 31436322
[TBL] [Abstract][Full Text] [Related]
16. Does neoadjuvant treatment before oncologic esophagectomy affect the postoperative quality of life? A prospective, longitudinal outcome study.
Hauser C; Patett C; von Schoenfels W; Heits N; Schafmayer C; Malchow B; Hampe J; Schniewind B; Becker T; Egberts JH
Dis Esophagus; 2015 Oct; 28(7):652-9. PubMed ID: 25059631
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life among patients cured by surgery for esophageal cancer.
Lagergren P; Avery KN; Hughes R; Barham CP; Alderson D; Falk SJ; Blazeby JM
Cancer; 2007 Aug; 110(3):686-93. PubMed ID: 17582628
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
